SRPTSarepta Therapeutics, Inc.
Is the business good?
Margins widening. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is SRPT?
Sarepta Therapeutics, Inc. earns −7.1% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
Return on invested capital · cost of capital 9.0% · 16 points below what the capital costs: growth destroys value
- Operating margin
- −7.3%
Operating margin · Biotechnology median −77% · 12 months to Q2 2026
- Share count, year on year
- −1.1%
Share count, year on year · bought back, each share owns more of the company
- R&D as % of revenue
- 40%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −104% |
| FY2021 | −66% |
| FY2022 | −57% |
| FY2023 | −22% |
| FY2024 | 11% |
| FY2025 | −32% |
Details›
- Operating margin12 months to Q2 2026
- −7.3%
- Net margin12 months to Q2 2026
- −6.9%
- Free cash flow margin
- 4.2%
- R&D as % of revenue
- 40%
- Revenue, trailing twelve months
- $1.97B
- Free cash flow, trailing twelve months
- $82M
- Net income, trailing twelve months
- −$137M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −7.1%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.